Marcio Andrade‐Campos

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Amy E. DeZern, Marcio Andrade‐Campos et al. · Clinical Cancer Research · 2016 · 95 citations · Full text

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 80 citations · Full text

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

Sara Alonso, Laura Magnano, Miguel Alcoceba et al. · British Journal of Haematology · 2017 · 76 citations · Full text

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease

Marcio Andrade‐Campos, Pilar Alfonso, Pilar Irún et al. · Orphanet Journal of Rare Diseases · 2017 · 44 citations · Full text

Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features

Xavier Calvo, Nieves García-Gisbert, Ivonne Párraga et al. · Blood Advances · 2020 · 39 citations · Full text